EXACTA · UNITED STATES
RESILIENT trial
Nagarkar R and colleagues • Oncotarget • 2019
- DOI
- 10.18632/oncotarget.27188
- Design
- Single-arm, open-label phase II/III study of refractory solid tumors.
- Population
- 190 enrolled; 143 began treatment; 126 evaluable.
- Endpoints
- Objective response, progression-free survival, and quality of life.
- Reported results
- Objective response occurred in 54/126 evaluable patients (42.9%; 95% CI 34.3–51.4%).
- Limitations
- No randomized comparator; attrition and evaluable-patient analysis limit inference. Results are not a guarantee for an individual.
- Funding and conflicts
- Funded entirely by Datar Cancer Genetics. The publication discloses company-employed authors.